Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses
Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.
- Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.
- The collaboration is founded on a $42 million award to DIOSynVax by the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development of a broadly protective Betacoronavirus vaccine through to a Phase I/II clinical trial.
- Ethris will receive up to $20M to design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs.
- The company has established its proprietary platforms to design and manufacture next-generation, well-tolerated, mRNA drug candidates with unparalleled LNP stability.